A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of SIM0237 in Adult Participants with Advanced Solid Tumors

Stopped An internal business decision, not based on safety or regulatory considerations.

Conditions

• Locally Advanced Unresectable or Metastatic Solid Tumor

Interventions

• DRUG: SIM0237

Sponsor

Jiangsu Simcere Pharmaceutical Co., Ltd.

Collaborators

• [object Object]
• [object Object]